Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ACADEMIA
ACADEMIA
- Drug-Use Result Surveys Should Be Conducted in Elaborate Manner: Dr Narukawa
March 25, 2015
- Yervoy Extends Survival of Terminal Melanoma Patients, Same Might Hold True for Other Immunotherapies: Prof.
March 19, 2015
- Researcher Has High Hopes for Immunotherapies as Fourth Pillar of Cancer Treatment
March 17, 2015
- Large-Scale Genomic Screening Project Gets Underway to Make Gene Database of 4,500 Cancer Patients
March 12, 2015
- Urological Cancer Society to Be Inaugurated in October
March 12, 2015
- Interview on SGLT-2 Inhibitor Use (2): Prof. Watada Calls for Caution in Analyzing EPPV Data
March 9, 2015
- Interview on SGLT-2 Inhibitor Use (1): Prof. Ueki Says Flat Sales Reflect Cautious Prescribing by Physicians
March 6, 2015
- Astellas, Nagasaki Univ. Extend Joint Research Deal for Dengue Fever by 1 Year
March 3, 2015
- No Problems Found with Integrity of CASE-J Data Analyses: Kyoto Univ.
March 2, 2015
- Govt-Backed Research Center Looks to License Malaria Vaccine to Mega Pharma
February 27, 2015
- Keio Researcher to Launch Clinical Trial on Repositioned AD Treatment in April
February 9, 2015
- Yamagata Univ. Hospital Introduces Anticancer Agent Dispensing Robot
January 23, 2015
- Nagoya University Concludes Diovan Study Data Trustworthy
December 24, 2014
- AGs Could Hinder Optimization of Healthcare Spending, Reduce Patients’ Options: Prof. Sakamaki
December 24, 2014
- Jikei Concludes Event Data Unnatural in Diovan Study
December 15, 2014
- British Medical Journal Retracts Sub-Analysis Paper of VART Study
December 11, 2014
- Cancer Researchers Call for Academia-Industry Collaboration via Japan NIH
December 9, 2014
- 22 Seeds Supported by Drug Discovery Support Network So Far: Dr Kurebayashi of NIBIO
December 9, 2014
- AIDS Treatment Extends Lives, but Many Problems Remain: Dr Mitsuya
December 1, 2014
- J-ARF Moving Into Full Gear as Academic Research Organization
December 1, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…